Taysha Gene Therapies Inc. (TSHA) NASDAQ
$1.21 0.03 (2.54%)
Market Cap: $75.56M
As of 02/03/23 04:00 PM EST. Market closed.
Taysha Gene Therapies Inc. (TSHA) NASDAQ
$1.21 0.03 (2.54%)
Market Cap: $75.56M
As of 02/03/23 04:00 PM EST. Market closed.
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an ... read more
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Manning Paul B | Director | Oct 31, 2022 | Buy | $2.00 | 1,500,000 | 3,000,000 | 1,642,202 | Nov 02, 2022, 04:09 PM |
| Alam Kamran | Chief Financial Officer | Aug 23, 2022 | Sale | $3.47 | 3,325 | 11,538 | 266,121 | Aug 24, 2022, 04:47 PM |
| Alam Kamran | Chief Financial Officer | Aug 19, 2022 | Sale | $3.75 | 11,482 | 43,058 | 279,163 | Aug 22, 2022, 08:05 PM |
| Alam Kamran | Chief Financial Officer | Aug 18, 2022 | Sale | $3.87 | 7,476 | 28,932 | 290,645 | Aug 22, 2022, 08:05 PM |
| Alam Kamran | Chief Financial Officer | Aug 22, 2022 | Sale | $3.50 | 9,717 | 34,010 | 269,446 | Aug 22, 2022, 08:05 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jul 06, 2022 | Sale | $3.79 | 8,956 | 33,943 | 530,589 | Jul 07, 2022, 04:30 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jul 05, 2022 | Sale | $3.51 | 3,905 | 13,707 | 539,545 | Jul 07, 2022, 04:30 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jul 01, 2022 | Sale | $3.53 | 23,923 | 84,448 | 543,450 | Jul 01, 2022, 06:55 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jun 30, 2022 | Sale | $3.72 | 13,892 | 51,678 | 567,373 | Jul 01, 2022, 06:55 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jun 29, 2022 | Sale | $3.81 | 12,324 | 46,954 | 581,265 | Jul 01, 2022, 06:55 PM |
| Manning Paul B | Director | Feb 03, 2022 | Buy | $7.84 | 26,602 | 208,560 | 2,091,704 | Feb 04, 2022, 08:28 AM |
| Manning Paul B | Director | Feb 03, 2022 | Buy | $7.84 | 50,000 | 392,000 | 142,202 | Feb 04, 2022, 08:28 AM |
| Manning Paul B | Director | Feb 02, 2022 | Buy | $7.77 | 67,000 | 520,590 | 2,065,102 | Feb 04, 2022, 08:28 AM |
| Manning Paul B | Director | Feb 02, 2022 | Buy | $7.77 | 58,000 | 450,660 | 92,202 | Feb 04, 2022, 08:28 AM |
| Nagendran Sukumar | Director | Feb 02, 2022 | Buy | $8.01 | 10,000 | 80,100 | 29,226 | Feb 03, 2022, 09:21 AM |
| Donenberg Phillip B. | Director | Feb 02, 2022 | Buy | $7.78 | 3,000 | 23,340 | 3,000 | Feb 03, 2022, 07:04 AM |
| Session R.A. II | President and CEO | Nov 23, 2021 | Buy | $12.44 | 42,518 | 529,102 | 9,190,920 | Dec 08, 2021, 04:05 PM |
| Manning Paul B | Director | Nov 24, 2021 | Buy | $13.19 | 2,202 | 29,044 | 34,202 | Nov 29, 2021, 05:01 PM |
| Manning Paul B | Director | Nov 23, 2021 | Buy | $12.54 | 20,000 | 250,800 | 32,000 | Nov 24, 2021, 07:58 AM |
| Alam Kamran | Chief Financial Officer | Aug 20, 2021 | Sale | $16.78 | 11,840 | 198,649 | 300,215 | Aug 20, 2021, 05:52 PM |
| Alam Kamran | Chief Financial Officer | Aug 19, 2021 | Sale | $16.47 | 9,967 | 164,175 | 310,574 | Aug 20, 2021, 05:52 PM |
| Alam Kamran | Chief Financial Officer | Aug 18, 2021 | Sale | $17.35 | 11,193 | 194,199 | 319,928 | Aug 20, 2021, 05:52 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jul 01, 2021 | Sale | $21.12 | 19,706 | 416,191 | 593,589 | Jul 01, 2021, 06:32 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jun 30, 2021 | Sale | $21.79 | 20,076 | 437,494 | 619,997 | Jul 01, 2021, 06:32 PM |
| PRASAD SUYASH | CMO and Head of R&D | Jun 29, 2021 | Sale | $23.82 | 39,218 | 934,251 | 637,533 | Jul 01, 2021, 06:32 PM |
| Manning Paul B | Director | May 14, 2021 | Buy | $20.98 | 12,000 | 251,760 | 12,000 | May 17, 2021, 07:48 AM |
| Owner | Relationship | Date | Value($) |
| Manning Paul B | Director | 10/31/2022 | 3,000,000 |
| Alam Kamran | Chief Financial Officer | 08/23/2022 | 11,538 |
| Alam Kamran | Chief Financial Officer | 08/19/2022 | 43,058 |
| Alam Kamran | Chief Financial Officer | 08/18/2022 | 28,932 |
| Alam Kamran | Chief Financial Officer | 08/22/2022 | 34,010 |
| PRASAD SUYASH | CMO and Head of R&D | 07/06/2022 | 33,943 |
| PRASAD SUYASH | CMO and Head of R&D | 07/05/2022 | 13,707 |
| PRASAD SUYASH | CMO and Head of R&D | 07/01/2022 | 84,448 |
| PRASAD SUYASH | CMO and Head of R&D | 06/30/2022 | 51,678 |
| PRASAD SUYASH | CMO and Head of R&D | 06/29/2022 | 46,954 |
| Manning Paul B | Director | 02/03/2022 | 208,560 |
| Manning Paul B | Director | 02/03/2022 | 392,000 |
| Manning Paul B | Director | 02/02/2022 | 520,590 |
| Manning Paul B | Director | 02/02/2022 | 450,660 |
| Nagendran Sukumar | Director | 02/02/2022 | 80,100 |
| Donenberg Phillip B. | Director | 02/02/2022 | 23,340 |
| Session R.A. II | President and CEO | 11/23/2021 | 529,102 |
| Manning Paul B | Director | 11/24/2021 | 29,044 |
| Manning Paul B | Director | 11/23/2021 | 250,800 |
| Alam Kamran | Chief Financial Officer | 08/20/2021 | 198,649 |
| Alam Kamran | Chief Financial Officer | 08/19/2021 | 164,175 |
| Alam Kamran | Chief Financial Officer | 08/18/2021 | 194,199 |
| PRASAD SUYASH | CMO and Head of R&D | 07/01/2021 | 416,191 |
| PRASAD SUYASH | CMO and Head of R&D | 06/30/2021 | 437,494 |
| PRASAD SUYASH | CMO and Head of R&D | 06/29/2021 | 934,251 |
| Manning Paul B | Director | 05/14/2021 | 251,760 |
Period of Report: 09/30/2022
10-K/10-Q Filings: View